These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 33820953)

  • 1. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer.
    Stultz J; Fong L
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):697-717. PubMed ID: 33820953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy.
    Peng S; Hu P; Xiao YT; Lu W; Guo D; Hu S; Xie J; Wang M; Yu W; Yang J; Chen H; Zhang X; Zhu Y; Wang Y; Yang Y; Zhu G; Chen S; Wang J; Zhang B; Chen W; Wu H; Sun Z; Ding T; Zhang H; Yi Z; Liu M; Ren S
    Clin Cancer Res; 2022 Feb; 28(3):552-567. PubMed ID: 34740924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate Cancer Immunotherapy-Finally in From the Cold?
    Runcie KD; Dallos MC
    Curr Oncol Rep; 2021 Jun; 23(8):88. PubMed ID: 34125308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in and prospects of immunotherapy for prostate cancer.
    Liu D; Wang L; Guo Y
    Cancer Lett; 2024 Oct; 601():217155. PubMed ID: 39127338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer immunotherapy: where are we and where are we going?
    De Velasco MA; Uemura H
    Curr Opin Urol; 2018 Jan; 28(1):15-24. PubMed ID: 29095729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.
    Wong RL; Yu EY
    Curr Treat Options Oncol; 2021 Jan; 22(2):13. PubMed ID: 33433743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy.
    Prokhnevska N; Emerson DA; Kissick HT; Redmond WL
    Adv Exp Med Biol; 2019; 1210():121-147. PubMed ID: 31900908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
    Sun BL
    Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
    Rathi N; McFarland TR; Nussenzveig R; Agarwal N; Swami U
    Drugs; 2021 Feb; 81(2):191-206. PubMed ID: 33369720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for prostate cancer: False promises or true hope?
    Rekoske BT; McNeel DG
    Cancer; 2016 Dec; 122(23):3598-3607. PubMed ID: 27649312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies.
    Datta M; Coussens LM; Nishikawa H; Hodi FS; Jain RK
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():165-174. PubMed ID: 31099649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer.
    Nair SS; Weil R; Dovey Z; Davis A; Tewari AK
    Urol Clin North Am; 2020 Nov; 47(4S):e17-e54. PubMed ID: 33446323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive review of immunotherapies in prostate cancer.
    Maia MC; Hansen AR
    Crit Rev Oncol Hematol; 2017 May; 113():292-303. PubMed ID: 28427519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the tumor-immune microenvironment in prostate cancer.
    Dong L; Myers KV; Pienta KJ
    Curr Opin Oncol; 2021 May; 33(3):231-237. PubMed ID: 33606403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilizing precision medicine to modulate the prostate tumor microenvironment and enhance immunotherapy.
    Olson B; Patnaik A
    Urol Oncol; 2019 Aug; 37(8):535-542. PubMed ID: 30503851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy of prostate cancer: identification of new treatments and targets for therapy, and role of WAP domain-containing proteins.
    Galustian C; Vyakarnam A; Elhage O; Hickman O; Dasgupta P; Smith RA
    Biochem Soc Trans; 2011 Oct; 39(5):1433-6. PubMed ID: 21936828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutibacterium acnes Induces the Expression of Immunosuppressive Genes in Macrophages and is Associated with an Increase of Regulatory T-Cells in Prostate Cancer.
    Davidsson S; Carlsson J; Greenberg L; Wijkander J; Söderquist B; Erlandsson A
    Microbiol Spectr; 2021 Dec; 9(3):e0149721. PubMed ID: 34937192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel?
    von Amsberg G; Alsdorf W; Karagiannis P; Coym A; Kaune M; Werner S; Graefen M; Bokemeyer C; Merkens L; Dyshlovoy SA
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor.
    Lou DY; Fong L
    Urol Oncol; 2016 Apr; 34(4):182-92. PubMed ID: 24495446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy.
    Anker JF; Naseem AF; Mok H; Schaeffer AJ; Abdulkadir SA; Thumbikat P
    Nat Commun; 2018 Apr; 9(1):1591. PubMed ID: 29686284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.